Observance in adults infected by the HIV: Study of a prophylaxis of opportunistic infections with cotrimoxazole in the Ivory Coast;Observance chez les adultes infectés par le VIH: Étude d'une prophylaxie des infections opportunistes par le cotrimoxazole en Côte d'Ivoire

Presse Medicale

Volumn 33, Issue 9 I, 2004, Pages 595-600

  Gourvellec, G ^a   Anglaret, Xavier ^a,b   Toure S ^a   Huet C ^a   Dakoury Dogbo, N ^a   Lafont, S ^a,b   N'Dri Yoman, T ^a,c   Chene G ^a,b   Salamon, R ^a,b  

^a Programme PAC CI   (Côte d’Ivoire)

^b INSERM   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE YOPOUGON   (Côte d’Ivoire)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE;

ADULT; AFRICA; ARTICLE; BLISTER PACK; CONTROLLED STUDY; COTE D'IVOIRE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; TABLET; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 2942705743     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(04)98683-6     Document Type: Article

References (33)

1. Grant A, Djomand G, De Cock K. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS 1997; 11 Suppl B: S43-54.
2. Anglaret X, Messou E, Ouassa T et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 2003; 17: 575-84.
3. World health organizaton, Unaids. Preventive therapy against tuberculosis in people living with HIV. Wkly Epidemiol Rec 1999; 74: 385-400.
4. Unaids/Who. Provisional Who/Unaids secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa.http://www.unaids.org/publications/documents/care/general/ recommendation-eng.pdf.
5. Morse EV, Simon PM, Coburn M, Hyslop N, Greespan D, Balson PM. Determinants of subject compliance within in experimental anti-HIV drug protocol. Soc Sci med 1991; 32: 1161-7.
6. Sobel A. L'observance en matière de santé. Presse Med 1997; 26: 356-7.
7. Munzenberger N, Cassuto JP, Gastaut JA, Souville M, Morin M, Moatti JP. L'observance au cours des essais thérapeutiques dans l'infection à VIH. Presse Med 1997; 26: 358-65.
8. Lerner BH, Gulick RM, Nubler NN. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV-disease. Ann Intern Med 1998; 129: 573-8.
9. Macilwain C. Better adherence vital in AIDS therapies. Nature 1997; 390: 326.
10. Godfrey E, Stanley K. Clinical research units for the treatment of the patients with HIV disease: operational issues and components needed to conduct clinical trials. J Acquir Immune Defic Syndrome 1993; 6: 567-74.
11. Pekovic V, Mayanja H, Vjecha M et al. Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. J Clin Epidemiol 1996; 51: 597-607.
12. Zachariah R, Harries A, Arendt V et al. Compliance with cotrimozaxole prophylaxis for the prevention of opportunistic infections in HIV-positive tuberculosis patients in Thyolo district, Malawi. Int J Tuberc Lung Dis 2001; 5: 843-6.
13. Anglaret X, Chene G, Attia A et al. Early chemoprophyalxis with trimetoprim-sulphamethoxazole for HIV-1 infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353: 1462-68.
14. Petchey R, Murphy E. Patient compliance. BMJ 1992; 305: 1434.
15. Meredith PA. Patient compliance. BMJ 1992; 305: 1434.
16. Pullar T, Kumar S, Feely M. Compliance in clinical trials. Ann Rheum Dis 1989; 48: 871-5.
17. Boudes P. Drug compliance in therapeutic trials: a review. Control Clin Trials 1998; 19: 257-68.
18. Urquhart J. Compliance and clinical trials. Lancet 1991; 337: 1224-5.
19. Wafaie W, Gernard I, Ernest J, David J. Rationale and design of the Tanzania vitamin and HIV infection trial. Control Clin trials 1999; 20: 75-90.
20. Vander Stichele R. Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin pharmacol 1991; 41: 27-35.
21. Rudd P, Byyny RL, Zachary V et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 1989; 48: 169-76.
22. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990; 150: 1509-10.
23. Lanièce I, Desclaux A, Ciss M, Diop K, Ndiaye B. L'observance des traitements antirétroviraux et ses déterminants. Analyse quantitative. In: Desclaux A, Lanièce I, Ndoye I, Taverne B, eds. L'initiative sénégalaise d'accès aux traitements antirétroviraux. Analyses économiques, sociales, comportementales et médicales. Paris; ANRS, Collection Sciences Sociales et Sida, 2002: 201-16.
24. Stephenson BJ, Rowe BH, Haynes RB. Is the patient taking the treatment as prescribed? JAMA 1993; 269: 2779-81.
25. Bouhnik AD, Chesney M, Carrieri P et al. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr 2002; 31: 5149-53.
26. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159: 733-40.
27. Macharia WM, Leon G, Rowe BH, Stephenson BJ, Haynes RB. An overview of interventions to improve compliance with appointment keeping for medical services. JAMA 1992; 267: 1813-17.
28. Feely M, Kumar S, Tindall H, Pullar T. Assessing compliance: Is retum tablet count worthwhile? Br J Clin Pharmacol 1981; 26: 641P-2P.
29. Mwinga A, Hosp M, Godfrey-Faussett R et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-57.
30. Giuffrida A, Torgerson DJ. Should we pay the patient? review of financial incentives to enhance patient compliance. BMJ 1997; 315: 703-7.
31. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999; 52: 1143-56.
32. Brou H, Oesgrées du Loû A, Souville M. Prophylaxie des infections opportunistes par le cotrimoxazole chez les patients infectés par le VIH en Côte d'Ivoire: connaissances et pratiques des médecins et des personnels soignants. In: Msellati P, Vidal L, Moatti J, eds. L'accès aux traitements du VIH/Sida en Côte d'Ivoire. Évaluation de l'Initative Onusida/Ministère de la santé publique, aspects économiques, sociaux et comportementaux. Paris: ANRS, Collection Sciences Sociales et Sida, 2001: 201-16.
33. Pradier C, Bentz L, Spire B et al. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy. French prospective controlled study. HIV Clin Trials 2003; 4: 121-31.